Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Oct 3;93(7):763-9.
doi: 10.1038/sj.bjc.6602748.

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

V Georgoulias  1 , A Agelidou, K Syrigos, A Rapti, M Agelidou, J Nikolakopoulos, A Polyzos, A Athanasiadis, E Tselepatiotis, N Androulakis, K Kalbakis, G Samonis, D Mavroudis
Affiliations
Clinical Trial

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

V Georgoulias et al. Br J Cancer. .

Abstract

The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n = 147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m(-2), day 1 and 100 mg m(-2), day 8) and cisplatin (80 mg m(-2), day 8) (IC; n = 74) or CDDP (80 mg m(-2), day 1) (C; n = 73) every 3 weeks. Patients treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P = 0.933). The 1-year survival rate was 34.3% for IC-treated patients and 31.7% for C-treated patients. Cox's regression analysis revealed that response to treatment (hazard ratio (HR) = 2.787; 95% confidence interval (CI): 1.1578-4.922) and performance status (HR = 1.865; 95% CI: 1.199-2.872) was independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8-32.2%) for IC-treated patients and 7.0% (95% CI: 1.15-13.6%) for C-treated patients (P = 0.012); tumour growth control (partial remission (PR) + stable disease (SD)) was observed in 26 (38%) IC and 25 (36%) C patients (P = 0.878). There was no difference in terms of quality of life between the two chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly higher in the IC- than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of patients treated with IC and C regimens.
See this image and copyright information in PMC

References

    1. Agelaki S, Bania H, Kouroussis Ch, Blazoyiannakis G, Souglakos J, Tsiafaki X, Kalbakis K, Rapti A, Androulakis N, Georgoulias V, Papadakis E (2001) Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. Lung Cancer 34(Suppl 4): 77–80 - PubMed
    1. Androulakis N, Kouroussis CH, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulias V (1998) Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127–1130 - PubMed
    1. Belani CP (1993) Multimodality management of regionally advanced non-small cell lung cancer. Semin Onco 20: 302–314 - PubMed
    1. Belani CP (1998) Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 25(3, Suppl 8): 10–14 - PubMed
    1. Boisseau M, Guichard S, Canal P (1996) Irinotecan (CPT-11): current status and perspectives. Exp Opin Invest Drugs 5: 613–626

MeSH terms